STAAR Surgical Tops Q2 Estimates With $93.5 Million Revenue as China EVO Plus Adoption Surges
Updated
Updated · Yahoo Finance · Aug 16
STAAR Surgical Tops Q2 Estimates With $93.5 Million Revenue as China EVO Plus Adoption Surges
2 articles · Updated · Yahoo Finance · Aug 16
Summary
$93.54 million in Q2 revenue and $0.25 adjusted EPS both beat expectations, with sales jumping 111% year over year and EBITDA reaching $20 million.
China drove the outperformance as EVO Plus adoption exceeded management's expectations and grew to roughly one-third of Chinese unit sales, alongside market share gains from laser-based procedures.
Operating margin improved to 10.8% from negative 67.6% a year earlier, while management said profitability and free cash flow returned on tighter cost control and lower restructuring and ERP-related drag ahead.
Double-digit growth in the U.S. and EMEA added support, though STAAR said the broader refractive market remains uneven and still faces tariff and currency headwinds, especially in Asia.